InsidersTradesSigma
Total declarations
Company
▲ Purchases (0 ops.)
▼ Sales (4 ops.)
Insider track record
CFODisclosed buys
0
Disclosed sells
4
T+90 hit rate
0%
T+90 mean return
-51.8%
Across 4 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Browse the full record of transactions filed by Shukla Sath, Chief Financial Officer. Officer active across 1 company, notably Spero Therapeutics, Inc.. Aggregated, 12 filings have been logged. Breakdown: 0 buy · 4 sells. Total volume traded: €29k. Activity tracked since 26 August 2021. The latest transaction was filed on 3 February 2025 (Attribution). Regulator: SEC (Form 4). The full history is openly available.
Declarations12 total
751,407 shares0Common StockSEC:0000950170-25-014850:0
2,757 shares@ US$1.3511.5% of flowCommon StockSEC:0000950170-24-101993:0
14,800 shares@ US$1.3262.5% of flowCommon StockSEC:0000950170-24-092170:0
679,501 shares0Common StockSEC:0000950170-24-011487:0
1,854 shares@ US$1.267.4% of flowCommon StockSEC:0000950170-23-045441:0
266,000 shares0Common StockSEC:0000950170-23-037973:0
265,957 shares0Common StockSEC:0000899243-23-003945:0
6,017 shares@ US$0.893818.5% of flowCommon StockSEC:0000899243-22-030087:0
38,014 shares0Common StockSEC:0000899243-22-004593
38,014 shares0Common StockSEC:0000899243-22-004593:0
24,067 shares0Common StockSEC:0000899243-21-034498
24,067 shares0Common StockSEC:0000899243-21-034498:0
12 of 12 declarations
About Shukla Sath
Sath Shukla is the Chief Financial Officer of Spero Therapeutics, Inc., a biopharmaceutical company focused on developing innovative treatments. In his role, he oversees financial operations and contributes to the company's growth strategy. Sath Shukla plays a crucial role in managing financial resources and optimizing Spero's economic performance.
